We Develop Novel Therapies to Address Unmet Needs

At iVEAcare, we are focused on developing and commercializing next generation neuromodulation technology platforms to treat patients suffering from chronic diseases.

About us

iVEAcare is developing innovative neuromodulation therapy to treat unmet clinical needs impacting large patient populations.

 

 

 Our Address:
1905 County Road C West
Roseville, MN 55113

 

Our Supporters

We are serial entrepreneurs, investors, and operators with extensive experience in implantable medical devices who have successfully founded multiple companies in the bioelectronics space. We partner with leading physicians to solve burdening chronic conditions and are supported by venture capital partners with deep domain expertise.


Meet the Team

Todd Kerkow

Todd Kerkow

Founder, President, and CEO

Todd has dedicated his career of 25+ years to develop and commercially deliver medical technology that is meaningful for patients, physicians, and investors.  Todd has worked in large companies such as Guidant and Boston Scientific and small companies such as Cameron Health, Microchips Biotech, and Cardionomic.  Todd’s persistent focus on solving problems has contributed significantly to advancements in medical technology.

Prior to iVEAcare, Todd was COO at NuXcel, a medical device accelerator. While at Cardionomic, Todd was Chief Technology Officer responsible for Research, Development, and Operations. He led the development, manufacturing, and clinical validation of the Cardiac Pulmonary Nerve Stimulation (CPNSTM) system, culminating in a successful Phase 1 Pilot Study.  Prior to Cardionomic, Todd was Vice President of Development and Commercialization at Microchips Biotech, which created a successful prototype implantable drug delivery device.

While at Cameron Health, Todd was Vice President of Product Development where he led the creation of the world’s first commercially available subcutaneous implantable defibrillator (S-ICD).  Boston Scientific purchased Cameron Health in a deal valued in excess of $500M, after which Todd successfully led the integration activities that blended Cameron Health into Boston Scientific.  At Boston Scientific, Todd was the company-wide Core Team Leader for the next generation subcutaneous implantable defibrillators (EMBLEMTM S-ICD, EMBLEMTM MRI S-ICD) and the company’s first leadless pacemaker (EMPOWERTM Modular Pacing System).

Prior to Cameron Health, Todd worked at Guidant in heart failure leads where he led the development of the ACUITYTM Spiral heart failure pacing lead.  Also at Guidant, he held leadership positions in manufacturing process development and engineering positions in manufacturing and on the Mini II, Mini III, and Mini IV implantable defibrillator development teams.

Todd is the holder of multiple patents. Todd has a BS and MS in Mechanical Engineering from the University of Minnesota.

Mudit K. Jain

Mudit K. Jain

Founder and Chairman of the Board

Mudit is a Founding General Partner of Treo Ventures, and the CEO and co-founder of NuXcel, a bioelectronics focused medical device accelerator. Mudit also co-founded ShiraTronics, Inc., where he serves as Chairman of the Board.

Mudit brings over two decades of medical device industry experience across company formation, R&D, business development, and venture capital, with a global perspective on healthcare based on his experiences in USA, Ireland, and India. Mudit has served on the boards of several medical device companies, from early concept to commercial growth stage, resulting in successful IPOs and M&A transactions.

Mudit currently serves on the boards of CVRx, (NSDQ: CVRX), Avivomed, Inc., Neuspera Medical, Inc., ShiraTronics, Inc., Neochord, Inc., NuXcel, and Noctrix Health, Inc. Some of his prior investments/board responsibilities include Inspire Medical Systems (NYSE: INSP), iRhythm Technologies (NSDQ: IRTC), Aptus Endosystems (Acqd. by Medtronic), CardioMEMS (Acqd. by St. Jude Medical), and Impres Medical (Acqd. by J&J). Mudit also serves on the External Advisory Board for Cleveland Clinic Innovations, Board of Visitors of the Graduate School at Duke University, External Advisory Board of John Hopkins University Center for Bioengineering Innovation and Design, and on the Board of One Heart Health, a healthcare focused non-profit focused on providing access to pediatric populations in underprivileged geographies.

Most recently, as a General Partner with Synergy Life Science Partners, Mudit delivered top quartile performance. In addition to his private venture capital experiences at Treo and Synergy Life Science Partners, Mudit also brings a strategic investment perspective gained during his tenure at Johnson & Johnson Development Corporation.

Prior to his investing career, Mudit held operational roles in the Cardiac Rhythm Management Division of Guidant Corporation, developing novel device technologies for heart failure, remote monitoring, and cardiac ablation. Mudit also played an important role in product development for start-ups like Epicor, Inc. (acquired: St. Jude Medical), and Cardiac Pathways Corporation (acquired: Boston Scientific). Mudit holds eight issued patents and has authored several peer reviewed publications.

Mudit graduated with a B.E. in Electrical Engineering from VNIT, Nagpur, India, where he was a gold medal recipient for academic achievements. He received his Ph.D. in Biomedical Engineering from Duke University, and his M.B.A. from The Wharton Business School, University of Pennsylvania.

Lynn Elliott

Lynn Elliott

Founder and Board Member

Lynn brings three decades of active implantable device experience in medical device innovation, R&D, manufacturing, clinical trials, and regulatory approvals to healthcare challenges. Lynn has a unique blend of experience in large medical device companies such as Guidant and Boston Scientific and small venture capital funded startups like Spinal Modulation, SacraMed, and ShiraTronics.

At Guidant, Lynn held leadership positions in Product Development and Research & Advanced Technologies and was a key driver of delivering pacemakers, implantable defibrillators and cardiac resynchronization device to the global market with revenues in excess $1B.

At Spinal Modulation, Lynn held the position of Chief Technology Officer and was a key driver of defining and delivering an innovative neurostimulation device for the management of chronic pain. Spinal Modulation was acquired by St Jude (Abbott) in a deal valued in excess of $500M.

Lynn holds over 20 US patents and has published numerous articles in peer reviewed publications.  Lynn graduated with a BS in Electrical Engineering from South Dakota School of Mines and Technology, an MS in Software Engineering from St Thomas University and advanced studies in Software Engineering at the University of Minnesota.

Press

 iVEAcare Launches with $27.5 Million in Series A Funding from Leading Medtech Investors

News provided by iVEAcare, Inc.

MINNEAPOLIS, April 22, 2024 — iVEAcare, a privately held, development stage medical device company, announced the close of a $27.5 million Series A financing. The financing was led by Vensana Capital, which was joined by Treo Ventures, Hatteras Venture Partners, and an undisclosed strategic partner. iVEAcare is the third spin-off from NuXcel, a medical device accelerator that is managed by Mudit K. Jain, PhD and Lynn Elliott and backed by Treo Ventures.

Concurrent with the financing, the company also announced the appointment of Todd Kerkow as President and CEO. Kerkow is a veteran of the medical device industry, with nearly three decades of experience at companies that include Guidant, Cameron Health, Boston Scientific, and Cardionomic.

“We are very fortunate to have such an experienced medical device investor group supporting iVEAcare, and I look forward to partnering with them to develop this novel neuromodulation technology. This Series A financing enables iVEAcare to deliver innovative neuromodulation therapy to patients and clinicians,” Kerkow said in prepared remarks.

“We are very excited to see the third spin-off from NuXcel attract support from a syndicate comprised of such seasoned investors. We look forward to working with our co-investors and the iVEAcare team to develop this impactful therapy,” added Treo Ventures General Partner, Tracy Pappas, and iVEAcare co-founder & Chairman, Mudit Jain.

“Neuromodulation is one of the most exciting frontiers in medicine,” said Vensana Capital Partner Amrinder Singh and Managing Partner Kirk Nielsen. “We are enthusiastic to partner with iVEAcare’s experienced team to advance a best-in-class therapy that will impact the lives of countless patients.”

iVEAcare is based in Roseville, MN. About iVEAcare: www.iveacare.com

Contact: info@iveacare.com

SOURCE iVEAcare, Inc.

Careers

We are hiring Software, Firmware, and Electrical Engineers.

We are hiring VP’s for Quality, Regulatory, and Clinicals.

If interested, please fill out the “Contact Us” information.

Contact Us